Literature DB >> 2082057

[Study on albumin metabolism in nephrotic syndrome].

Y Komatsu1.   

Abstract

Abnormalities in albumin metabolism in nephrotic syndrome are still controversial. In an attempt to clarify the pathogenesis of the alteration in albumin metabolism in nephrotic syndrome. 131I-human serum albumin (131I-HSA) of 10 microCi loading was intravenously injected to 10 nephrotic (7 minimal change, 3 membranous nephropathy) and 3 non-nephrotic patients. Kinetic study was made by means of two compartment analysis following the 131I-HSA administration. The results were as follows: 1. Albumin synthesis decreased to some extent in nephrotic syndrome. 2. Absolute albumin catabolic rate decreased in nephrotic syndrome. 3. Fractional disappearance rate of albumin (FDR) and albumin turnover rate increased in association with progression of nephrotic syndrome. Both albumin escape into the extravascular pool and urinary excretion rate of albumin also increased. 4. In comparison of two types of nephrotic syndrome, minimal change and membranous nephropathy, it was found that, although renal and peripheral vascular permeabilities increased in both types, minimal change tended to show higher permeability than membranous nephropathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082057

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  2 in total

1.  Two cases of minor glomerular abnormalities with proteinuria disproportionate to the degree of hypoproteinemia.

Authors:  Tsuyoshi Takashima; Koji Onozawa; Syuichi Rikitake; Tomoya Kishi; Motoaki Miyazono; Shigehisa Aoki; Takanobu Sakemi; Yuji Ikeda
Journal:  CEN Case Rep       Date:  2014-02-14

2.  Significance of technetium-99m human serum albumin diethylenetriamine pentaacetic acid scintigraphy in patients with nephrotic syndrome.

Authors:  Tsuyoshi Takashima; Tomoya Kishi; Koji Onozawa; Shuichi Rikitake; Motoaki Miyazono; Takateru Otsuka; Hiroyuki Irie; Ryuichi Iwakiri; Kazuma Fujimoto; Yuji Ikeda
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.